首页> 外文OA文献 >Current trends in vasopressor use to the operating room : a pharmacoepidemiologic study in French teaching and military hospitals
【2h】

Current trends in vasopressor use to the operating room : a pharmacoepidemiologic study in French teaching and military hospitals

机译:手术室使用升压药的最新趋势:法国教学和军事医院的药物流行病学研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objectives:\udPhenylephrine, ephedrine and norepinephrine are the vasopressors most commonly used in the operating room to treat anaesthesia-induced hypotension. Two new diluted forms of phenylephrine were released in 2011 (500 μg/10 mL and 500 μg/5 mL). We initiated a study to evaluate trends in the use of vasopressors in the operating room in French hospitals over the period 2011–2014.\ud\udMethods:\udWe conducted a longitudinal, retrospective, observational study between 2011 and 2014 in French teaching and military hospitals. A questionnaire was sent in February 2015 to hospital pharmacists of each centre to retrospectively collect the consumption of each type of vasopressor. Yearly numbers of vasopressor ampoules were divided by the yearly numbers of anaesthetics recorded. For each vasopressor, we calculated the number of ampoules per 100 anaesthetics recorded (/100A).\ud\udResults:\udThirty-two hospitals (82%) completed the questionnaire. One hundred per cent of hospitals had registered the diluted form of phenylephrine (61% had chosen the dilution 500 μg/10 mL), whereas concentrated ampoules were available in 68% of hospitals. Over the period, an exponential increase in the use of diluted phenylephrine was observed (from 1.0 ampoule/100A in 2012 to 31.7 in 2014), the use of ephedrine remained stable (26 ampoules and 17 prefilled syringe/100A), and use of norepinephrine trended upwards (from 6.7 to 8.2 ampoules/100A).\ud\udConclusions:\udThe use of diluted phenylephrine has exponentially increased without reducing consumption of other vasopressors. This trend might be secondary to practice changes in hypotension treatment following the release of French guidelines in 2013 related to fluid management, the restriction of indications of hydroxylethyl-starch solutions in 2013, and a better knowledge of the benefit of blood pressure optimisation to reduce postoperative morbidity.
机译:目标:\ ud苯肾上腺素,麻黄碱和去甲肾上腺素是手术室中最常用于治疗麻醉性低血压的血管加压药。 2011年发布了两种新的去氧肾上腺素稀释形式(500μg/ 10 mL和500μg/ 5 mL)。我们发起了一项研究,以评估2011-2014年间法国医院手术室使用血管加压药的趋势。\ ud \ ud方法:\ ud我们在2011年至2014年之间进行了纵向,回顾性,观察性研究,目的是研究法国的教学和军事用途医院。 2015年2月,向每个中心的医院药剂师发送了调查问卷,以回顾性收集每种类型的升压药的消费量。每年将血管加压药的安瓿数除以所记录的麻醉药的年数。对于每种升压药,我们计算了每100剂麻醉药(/ 100A)的安瓿数量。\ ud \ ud结果:\ ud有32家医院(82%)填写了问卷。百分之一百的医院已注册了去氧肾上腺素的稀释形式(61%的医院选择了500μg/ 10 mL的稀释溶液),而68%的医院提供了浓缩安瓿瓶。在此期间,观察到稀释的去氧肾上腺素的使用呈指数增长(从2012年的1.0安瓿/ 100A增至2014年的31.7),麻黄碱的使用保持稳定(26安瓿和17个预填充注射器/ 100A),去甲肾上腺素的使用\ ud \ ud结论:\ ud使用稀苯肾上腺素的使用呈指数增加,而没有减少其他血管加压药的消耗。这种趋势可能是继2013年法国有关液体管理的指南发布,2013年羟乙基淀粉溶液适应症的限制以及对降低血压降低血压的益处的更好了解之后降压治疗实践变化的继发发病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号